Klin Farmakol Farm. 2007;21(3):98-102

The importance of dosage intervals for the therapy using time-dependent antibiotics: Examples of therapeutic drug monitoring

Josef Šedivý1, Anna Jedličková1, Olga Černá2
1 Ústav klinické biochemie a laboratorní diagnostiky 1. LF UK a VFN, Praha
2 Klinika dětského a dorostového lékařství 1. LF UK a VFN, Praha

Based on growth/killing microbial parameters in vitro and individual drug concentration/time fluctuations, the rate of bactericidal effect of two time-dependent antibiotics, vancomycin and amoxicillin/clavulanate, was calculated to optimize the next therapy. Predicted time to decrease the number of viable bacteria to 10–6 (as compared with the start of therapy) was adopted as surrogate criterion of the bactericidal effect. Even of highly susceptible strains, microbial killing activity of time-dependent antibiotic agent ceases when its concentration declines under about 4 times the MIC-level. It takes place mainly at the end of too long intermittent dosage interval. For example, the dosage interval for standard oral forms of amoxicillin/clavulanate should not be longer than 8 hours. Shortening the dosage interval (being much more effective than higher dose administered intermittently) or continuous IV-infusion of standard daily dose of these antibiotics accelerates bactericidal effect in some pacients. On the other hand, the available therapeutic monitoring of vancomycine and the recommendation to hold its Cmin over 5 mg/L seems to be rational and satisfactory in the treatment of susceptible infections.

Keywords: vancomycin, amoxicillin/clavulanate, dosage interval, microbial growth/killing rates, therapeutic drug monitoring

Published: January 1, 2008  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Šedivý J, Jedličková A, Černá O. The importance of dosage intervals for the therapy using time-dependent antibiotics: Examples of therapeutic drug monitoring. Klin Farmakol Farm. 2007;21(3):98-102.
Download citation

References

  1. Andes D, Craig WA. In vivo activities of amoxicillin and amoxicillin-clavulanate against Streptococcus pneumoniae. Application to breakpoint determination. Antimicrob Agents Chemother 1998; 42: 2375-2379. Go to original source... Go to PubMed...
  2. Bouvier d´Yvoire MJY, Maire PH. Dosage regimens of antibacterials. Implications of a pharmacokinetic/pharmacodynamic model. Clin Drug Invest 1996; 11 (4): 229-239. Go to original source...
  3. Craig WA. Antibiotic selection factors and description of a hospital-based outpatient antibiotic program in the USA. Eur J Clin Microbiol Infect Dis 1995; 14: 636-642. Go to original source... Go to PubMed...
  4. Mouton JW, Vinks AA. Is continuous infusion of ?-lactam antibiotics worthwhile? Efficacy and pharmacokinetic considerations. J Antimicrob Chemother 1996; 38: 5-15. Go to original source... Go to PubMed...
  5. Neef C, van Gils SA, IJzerman WL. Analogy between temperature-dependent and concentration-dependent bacterial killing. Comput Biol Med 2002; 32 (6): 529-549. Go to original source... Go to PubMed...
  6. Proost JH, Meijer DKF. MW/PHARM, an integrated software package for drug dosage regimen calcula tion and therapeutic drug monitoring. Comput Biol Med 1992; 27 (3): 155-163. Go to original source... Go to PubMed...
  7. Šedivý J, Petkov V, Jirkovská A, Štambergová A, Ulbrichová Z, Lupínková J, Fejfarová V, Bém R. Optimalizace léčby amoxicilin/klavulanátem na základě PK/PD parametrů u nemocných s infekcí při syndromu diabetické nohy. Klin mikrobiol inf lék 2004; 10 (4): 167-175.
  8. Urbášková P. Rezistence bakterií k antibiotikům - vybrané metody. Praha: Trios, 1998.
  9. Zhi J, Nightingale CH, Quintiliani R. A pharmacodynamic model for the activity of antibiotics against microorganisms under nonsaturable conditions. J Pharm Sci 1986; 75 (11): 1063-1067. Go to original source... Go to PubMed...




Clinical Pharmacology and Pharmacy

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.